{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T15:57:56Z","timestamp":1788623876384,"version":"build-2803163510"},"reference-count":248,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T00:00:00Z","timestamp":1461974400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s00210-016-1247-1","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T03:00:37Z","timestamp":1461985237000},"page":"671-694","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Pharmacological treatment options for mast cell activation disease"],"prefix":"10.1007","volume":"389","author":[{"given":"Gerhard J.","family":"Molderings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Haenisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Brettner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Homann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Menzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz Ludwig","family":"Dumoulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Panse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Butterfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence B.","family":"Afrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,30]]},"reference":[{"key":"1247_CR1","doi-asserted-by":"crossref","unstructured":"Abdulkadir H, Grootens J, Kjellander M, Hellstram Lindberg E, Nilsson G, Ungerstedt J (2015) Histone deacetylase inhibitor SAHA mediates epigenetic silencing of KIT D816V mutated systemic mastocytosis primary mast cells and selective apoptosis of mutated mast cells. Blood;126: abstract 2834","DOI":"10.1182\/blood.V126.23.2834.2834"},{"key":"1247_CR2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF02482970","volume":"29","author":"S Adachi","year":"1999","unstructured":"Adachi S, Maruyama T, Kondo T, Todoroki T, Fukao K (1999) The prevention of postoperative intraperitoneal adhesions by tranilast: N-(3\u2032,4\u2032-dimethoxycinnamoyl)anthranilic acid. Surg Today 29:51\u201354","journal-title":"Surg Today"},{"key":"1247_CR3","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s12185-010-0605-x","volume":"91","author":"LB Afrin","year":"2010","unstructured":"Afrin LB (2010) Mast cell activation disorder masquerading as pure red cell aplasia. Int J Hematol 91:907\u2013908","journal-title":"Int J Hematol"},{"key":"1247_CR4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/MAJ.0b013e31821d41dd","volume":"342","author":"LB Afrin","year":"2011","unstructured":"Afrin LB (2011) Polycythemia from mast cell activation syndrome: lessons learned. Am J Med Sci 342:44\u201349","journal-title":"Am J Med Sci"},{"key":"1247_CR5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.7205\/MILMED-D-11-00111","volume":"177","author":"LB Afrin","year":"2012","unstructured":"Afrin LB (2012) Mast cell activation syndrome masquerading as agranulocytosis. Mil Med 177:113\u2013117","journal-title":"Mil Med"},{"key":"1247_CR6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/2162-3619-2-28","volume":"2","author":"LB Afrin","year":"2013","unstructured":"Afrin LB (2013) Utility of hydroxyurea in mast cell activation syndrome. Exp Hematol Oncol 2:28","journal-title":"Exp Hematol Oncol"},{"key":"1247_CR7","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1182\/blood.V126.23.5194.5194","volume":"126","author":"LB Afrin","year":"2015","unstructured":"Afrin LB (2015) Utility of continuous diphenhydramine infusion in severe mast cell activation syndrome. Blood 126:5194 abstract","journal-title":"Blood"},{"key":"1247_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5315\/wjh.v3.i1","volume":"3","author":"LB Afrin","year":"2014","unstructured":"Afrin LB, Molderings GJ (2014) A concise, practical guide to diagnostic assessment for mast cell activation disease. World J Hematol 3:1\u201317","journal-title":"World J Hematol"},{"key":"1247_CR9","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/ejh.12606","volume":"95","author":"LB Afrin","year":"2015","unstructured":"Afrin LB, Cichocki FM, Patel K, Molderings GJ (2015a) Successful treatment of mast cell activation syndrome with sunitinib. Eur J Haematol 95:595\u2013597","journal-title":"Eur J Haematol"},{"key":"1247_CR10","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bbi.2015.07.002","volume":"50","author":"LB Afrin","year":"2015","unstructured":"Afrin LB, P\u00f6hlau D, Raithel M, Haenisch B, Dumoulin FL, Homann J, Mauer UM, Harzer S, Molderings GJ (2015b) Mast cell activation disease: an underappreciated cause of neurologic and psychiatric symptoms and diseases. Brain Behav Immun 50:314\u2013321","journal-title":"Brain Behav Immun"},{"key":"1247_CR11","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1182\/blood-2008-08-175190","volume":"114","author":"KJ Aichberger","year":"2009","unstructured":"Aichberger KJ, Gleixner KV, Mirkina I, Cerny-Reiterer S, Peter B, Ferenc V, Kneidinger M, Baumgartner C, Mayerhofer M, Gruze A, Pickl WF, Sillaber C, Valent P (2009) Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs. Blood 114:5342\u20135351","journal-title":"Blood"},{"key":"1247_CR12","doi-asserted-by":"crossref","first-page":"950582","DOI":"10.1155\/2012\/950582","volume":"2012","author":"A Akhavein","year":"2012","unstructured":"Akhavein A, Patel NR, Minoyappa PK, Glover SC (2012) Allergic mastocytic gastroenteritis and colitis: an unexplained etiology in chronic abdominal pain and gastrointestinal dysmotility. Gastroenterol Res Pract 2012:950582","journal-title":"Gastroenterol Res Pract"},{"key":"1247_CR13","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","volume":"126","author":"C Akin","year":"2010","unstructured":"Akin C, Valent P, Metcalfe D (2010) Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol 126:1099\u20131104","journal-title":"J Allergy Clin Immunol"},{"key":"1247_CR14","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1124\/jpet.114.214122","volume":"349","author":"S Aldi","year":"2014","unstructured":"Aldi S, Takano KI, Tomita K, Koda K, Chan NY, Marino A, Salazar-Rodriguez M, Thurmond RL, Levi R (2014) Histamine H4-receptors inhibit mast cell renin release in ischemia\/reperfusion via PKC\u03b5-dependent aldehyde dehydrogenase type-2 activation. J Pharmacol Exp Ther 349:508\u2013517","journal-title":"J Pharmacol Exp Ther"},{"key":"1247_CR15","first-page":"373","volume":"24","author":"MG Alexandrakis","year":"2003","unstructured":"Alexandrakis MG, Kyriakou DS, Kempuraj D, Huang M, Boucher W, Seretakis D, Theoharides TC (2003) The isoflavone genistein inhibits proliferation and increases histamine content in human leukemic mast cells. Allergy Asthma Proc 24:373\u2013377","journal-title":"Allergy Asthma Proc"},{"key":"1247_CR16","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1161\/CIRCULATIONAHA.112.134304","volume":"126","author":"J Aman","year":"2012","unstructured":"Aman J, van Bezu J, Damanafshan A, Huveneers S, Eringa EC, Vogel SM, Groeneveld AB, Vonk Noordegraaf A, van Hinsbergh VW, van Nieuw Amerongen GP (2012) Effective treatment of edema and endothelial barrier dysfunction with imatinib. Circulation 126:2728\u20132738","journal-title":"Circulation"},{"key":"1247_CR17","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00210-012-0757-8","volume":"385","author":"P Anand","year":"2012","unstructured":"Anand P, Singh B, Jaggi AS, Singh N (2012) Mast cells: an expanding pathophysiological role from allergy to other disorders. Naunyn Schmiedeberg\u2019s Arch Pharmacol 385:657\u2013670","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"1247_CR18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000438605","volume":"38","author":"A Baba","year":"2016","unstructured":"Baba A, Tachi M, Ejima Y, Endo Y, Toyama H, Matsubara M, Saito K, Yamauchi M, Miura C, Kazama I (2016) Anti-allergic drugs tranilast and ketotifen dose-dependently exert mast cell-stabilizing properties. Cell Physiol Biochem 38:15\u201327","journal-title":"Cell Physiol Biochem"},{"key":"1247_CR19","first-page":"483","volume":"14","author":"S Babaei","year":"2012","unstructured":"Babaei S, Bayat M (2012) Effect of pentoxifylline administration on mast cell numbers and degranulation in a diabetic and normoglycemic rat model wound healing. Iran Red Crescent Med J 14:483\u2013487","journal-title":"Iran Red Crescent Med J"},{"key":"1247_CR20","doi-asserted-by":"crossref","first-page":"7989","DOI":"10.4049\/jimmunol.175.12.7989","volume":"175","author":"I Bachelet","year":"2005","unstructured":"Bachelet I, Munitz A, Moretta A, Moretta L, Levi-Schaffer F (2005) The inhibitory receptor IRp60 (CD300a) is expressed and functional on human mast cells. J Immunol 175:7989\u20137995","journal-title":"J Immunol"},{"key":"1247_CR21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3343\/alm.2013.33.2.125","volume":"33","author":"MH Bae","year":"2013","unstructured":"Bae MH, Kim HK, Park CJ, Seo EJ, Park SH, Cho YU, Jang S, Chi HS, Lee KH (2013) A case of systemic mastocytosis associated with acute myeloid leukemia terminating as aleukemic mast cell leukemia after allogeneic hematopoietic stem cell transplantation. Ann Lab Med 33:125\u2013129","journal-title":"Ann Lab Med"},{"key":"1247_CR22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.cccn.2003.08.015","volume":"338","author":"OS Baek","year":"2003","unstructured":"Baek OS, Kang OH, Choi YA, Choi SC, Kim TH, Nah YH, Kwon DY, Kim YK, Kim YH, Bae KH, Lim JP, Lee YM (2003) Curcumin inhibits protease-activated receptor-2 and -4-mediated mast cell activation. Clin Chim Acta 338:135\u2013141","journal-title":"Clin Chim Acta"},{"key":"1247_CR23","unstructured":"Bairlein M (2010) Characterization of the small molecule kinase inhibitor SU11248 (sunitinib\/SUTENT) in vitro and in vivo\u2014towards response prediction in cancer therapy with kinase inhibitors. TU Munich, Munich, Germany, Medical thesis"},{"key":"1247_CR24","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","volume":"126","author":"S Barete","year":"2015","unstructured":"Barete S, Lortholary O, Damaj G, Hirsch I, Chandesris MO, Elie C, Hamidou M, Durieu I, Suarez F, Grosbois B, Limal N, Gyan E, Larroche C, Guillet G, Kahn JE, Casassus P, Amazzough K, Coignard-Biehler H, Georgin-Lavialle S, Lhermitte L, Fraitag S, Canioni D, Dubreuil P, Hermine O (2015) Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. Blood 126:1009\u20131016","journal-title":"Blood"},{"key":"1247_CR25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.anai.2012.02.021","volume":"108","author":"MC Bell","year":"2012","unstructured":"Bell MC, Jackson DJ (2012) Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab. Ann Allergy Asthma Immunol 108:383\u2013384","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1247_CR26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3324\/haematol.2013.098442","volume":"99","author":"S Bibi","year":"2014","unstructured":"Bibi S, Arslanhan MD, Langenfeld F, Jeanningros S, Cerny-Reiterer S, Hadzijusufovic E, Tchertanov L, Moriggl R, Valent P, Arock M (2014) Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy. Haematologica 99:417\u2013429","journal-title":"Haematologica"},{"key":"1247_CR27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0162-3109(99)00046-6","volume":"43","author":"M Bidri","year":"1999","unstructured":"Bidri M, Royer B, Averlant G, Bismuth G, Guillosson JJ, Arock M (1999) Inhibition of mouse mast cell proliferation and proinflammatory mediator release by benzodiazepines. Immunopharmacology 43:75\u201386","journal-title":"Immunopharmacology"},{"key":"1247_CR28","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/ajg.2010.487","volume":"106","author":"JR Biesiekierski","year":"2011","unstructured":"Biesiekierski JR, Newnham ED, Irving PM, Barrett JS, Haines M, Doecke JD, Shepherd SJ, Muir JG, Gibson PR (2011) Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol 106:508\u2013514","journal-title":"Am J Gastroenterol"},{"key":"1247_CR29","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.exphem.2010.05.006","volume":"38","author":"A B\u00f6hm","year":"2010","unstructured":"B\u00f6hm A, Sonneck K, Gleixner KV, Schuch K, Pickl WF, Blatt K, Peter B, Herrmann H, Schernthaner GH, Pehamberger H, Rabitsch W, Sperr WR, Valent P (2010) In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. Exp Hematol 38:744\u2013755","journal-title":"Exp Hematol"},{"key":"1247_CR30","doi-asserted-by":"crossref","unstructured":"Borzutzky A, Morales PS, Mezzano V, Nussbaum S, Burks W (2014) Induction of remission of frequent idiopathic anaphylaxis with rituximab. AAAAI Meeting 28.2.-04.03, abstract 91","DOI":"10.1016\/j.jaci.2013.12.115"},{"key":"1247_CR31","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1600-065X.2007.00512.x","volume":"217","author":"JA Boyce","year":"2007","unstructured":"Boyce JA (2007) Mast cells and eicosanoid mediators: a system of reciprocal paracrine and autocrine regulation. Immunol Rev 217:168\u2013185","journal-title":"Immunol Rev"},{"key":"1247_CR32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1081-1206(10)60247-5","volume":"102","author":"RG Breslow","year":"2009","unstructured":"Breslow RG, Caiado J, Castells MC (2009) Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desenesitization. Ann Allergy Asthma Immunol 102:155\u2013160","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1247_CR33","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jaci.2013.02.019","volume":"132","author":"S Broesby-Olsen","year":"2013","unstructured":"Broesby-Olsen S, Kristensen T, Vestergaard H, Brixen K, M\u00f8ller MB, Bindslev-Jensen C, Mastocytosis Centre Odense University Hospital (MastOUH) (2013) KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis. J Allergy Clin Immunol 132:723\u2013728","journal-title":"J Allergy Clin Immunol"},{"issue":"Supplement 1","key":"1247_CR34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00011-004-0402-1","volume":"54","author":"H Broyd","year":"2005","unstructured":"Broyd H, Koffer A, Assem ESK (2005) Effect of cyclosporin-A on secretion from intact and permeabilised mast cells. Inflamm Res 54(Supplement 1):7\u20138","journal-title":"Inflamm Res"},{"key":"1247_CR35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000085560","volume":"114","author":"JH Butterfield","year":"2005","unstructured":"Butterfield JH (2005) Interferon treatment for hypereosinophilic syndromes ans systemic mastocytosis. Acta Haematol 114:26\u201340","journal-title":"Acta Haematol"},{"key":"1247_CR36","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.prostaglandins.2009.01.001","volume":"88","author":"JH Butterfield","year":"2009","unstructured":"Butterfield JH (2009) Survey of aspirin administration in systemic mastocytosis. Prostaglandins Other Lipid Mediat 88:122\u2013124","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"1247_CR37","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.leukres.2015.11.004","volume":"40","author":"JH Butterfield","year":"2016","unstructured":"Butterfield JH, Chen D (2016) Response of patients with indolent systemic mastocytosis to tamoxifen citrate. Leuk Res 40:10\u201316","journal-title":"Leuk Res"},{"key":"1247_CR38","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000144042","volume":"147","author":"JH Butterfield","year":"2008","unstructured":"Butterfield JH, Weiler CR (2008) Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production. Int Arch Allergy Immunol 147:338\u2013343","journal-title":"Int Arch Allergy Immunol"},{"key":"1247_CR39","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.leukres.2004.05.003","volume":"29","author":"JH Butterfield","year":"2005","unstructured":"Butterfield JH, Tefferi A, Kozuh GF (2005) Successful treatment of systemic mastocytosis with high- dose interferon-alfa: long-term follow-up of a case. Leuk Res 29:131\u2013134","journal-title":"Leuk Res"},{"key":"1247_CR40","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1517\/14656566.2013.824424","volume":"14","author":"JC Cardet","year":"2013","unstructured":"Cardet JC, Akin C, Lee MJ (2013) Mastocytosis: update on pharmacotherapy and future directions. Expert Opin Pharmacother 14:2033\u20132045","journal-title":"Expert Opin Pharmacother"},{"key":"1247_CR41","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jaci.2007.03.032","volume":"119","author":"MC Carter","year":"2007","unstructured":"Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalfe DD (2007) Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol 119:1550\u20131551","journal-title":"J Allergy Clin Immunol"},{"key":"1247_CR42","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1046\/j.1365-2141.2002.03944.x","volume":"119","author":"P Casassus","year":"2002","unstructured":"Casassus P, Caillat-Vigneron N, Martin A, Simon J, Gallais V, Beaudry P, Eclache V, Laroche L, Lortholary P, Rapha\u00ebl M, Guillevin L, Lortholary O (2002) Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol 119:1090\u20131097","journal-title":"Br J Haematol"},{"key":"1247_CR43","doi-asserted-by":"crossref","unstructured":"Caughey GH (2016) Mast cell proteases as pharmacological targets. Eur J Pharmacol 778:44\u201355","DOI":"10.1016\/j.ejphar.2015.04.045"},{"key":"1247_CR44","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/ced.12000","volume":"38","author":"IJ Chan","year":"2013","unstructured":"Chan IJ, Kasprowicz S, Tharp MD (2013) Distinct signalling pathways for mutated KIT(V560G) and KIT(D816V) in mastocytosis. Clin Exp Dermatol 38:538\u2013544","journal-title":"Clin Exp Dermatol"},{"key":"1247_CR45","doi-asserted-by":"crossref","unstructured":"Chandesris MO, Damaj G, Canioni D, Brouzes C, Cabaret L, Hanssens K, Durieu I, Durupt S, Besnard S, Beyne-Rauzy O, Launay D, Schiffmann A, Niault M, Ranta D, Agape P, Faure C, Chantepie SP, Daguindau N, Bourgeet P, Dubreuil P, Lortholary O, Hermine O (2014) Treatment of advanced systemic mastocytosis with PKC412: the French compassionate use programme experience and historical comparison. ASH Meeting, abstract 3193","DOI":"10.1182\/blood.V124.21.3193.3193"},{"key":"1247_CR46","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1113\/jphysiol.1975.sp011091","volume":"251","author":"IB Chatterjee","year":"1975","unstructured":"Chatterjee IB, Gupta SD, Majumder AK, Nandi BK, Subramanian N (1975) Effect of ascorbic acid on histamine metabolism in scorbutic guinea-pigs. J Physiol 251:271\u2013279","journal-title":"J Physiol"},{"key":"1247_CR47","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1476-5381.1980.tb07919.x","volume":"69","author":"MK Church","year":"1980","unstructured":"Church MK, Gradidge CF (1980) Inhibition of histamine release from human lung in vitro by antihistamines and related drugs. Br J Pharmacol 69:663\u2013667","journal-title":"Br J Pharmacol"},{"key":"1247_CR48","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.acthis.2008.04.006","volume":"111","author":"E Cikler","year":"2009","unstructured":"Cikler E, Ersoy Y, Cetinel S, Ercan F (2009) The leukotriene d4 receptor antagonist, montelukast, inhibits mast cell degranulation in the dermis induced by water avoidance stress. Acta Histochem 111:112\u2013118","journal-title":"Acta Histochem"},{"key":"1247_CR49","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/JCP.0b013e3182196e50","volume":"31","author":"A Clemons","year":"2011","unstructured":"Clemons A, Vasiadi M, Kempuraj D, Kourelis T, Vandoros G, Theoharides TC (2011) Amitriptyline and prochlorperazine inhibit proinflammatory mediator release from human mast cells: possible relevance to chronic fatigue syndrome. J Clin Psychopharmacol 31:385\u2013387","journal-title":"J Clin Psychopharmacol"},{"key":"1247_CR50","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/bjh.12916","volume":"166","author":"SS Cohen","year":"2014","unstructured":"Cohen SS, Skovbo S, Vestergaard H, Kristensen T, M\u00f8ller M, Bindslev-Jensen C, Fryzek JP, Broesby-Olsen S (2014) Epidemiology of systemic mastocytosis in Denmark. Br J Haematol 166:521\u2013528","journal-title":"Br J Haematol"},{"key":"1247_CR51","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jss.2006.05.044","volume":"141","author":"K Cooper","year":"2007","unstructured":"Cooper K, Young J, Wadsworth S, Cui H, diZerega GS, Rodgers KE (2007) Reduction of post-surgical adhesion formation with tranilast. J Surg Res 141:153\u2013161","journal-title":"J Surg Res"},{"key":"1247_CR52","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1182\/blood-2004-06-2189","volume":"104","author":"AS Corbin","year":"2004","unstructured":"Corbin AS, Griswold IJ, La Ros\u00e9e P, Yee KW, Heinrich MC, Reimer CL, Druker BJ, Deininger MW (2004) Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. Blood 104:3754\u20133757","journal-title":"Blood"},{"key":"1247_CR53","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5070\/D30FK211ZH","volume":"16","author":"O Correia","year":"2010","unstructured":"Correia O, Duarte AF, Quirino P, Azevedo R, Delgado L (2010) Cutaneous mastocytosis: two pediatric cases treated with topical pimecrolimus. Dermatol Online J 16:8","journal-title":"Dermatol Online J"},{"key":"1247_CR54","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2141.2008.07038.x","volume":"141","author":"G Damaj","year":"2008","unstructured":"Damaj G, Bernit E, Ghez D, Claisse JF, Schleinitz N, Harl\u00e9 JR, Canioni D, Hermine O (2008) Thalidomide in advanced mastocytosis. Br J Haematol 141:249\u2013253","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"1247_CR55","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2826.2008.01674.x","volume":"20","author":"D Filippis De","year":"2008","unstructured":"De Filippis D, D\u2019Amico A, Iuvone T (2008) Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation. J Neuroendocrinol 20(Suppl 1):20\u201325","journal-title":"J Neuroendocrinol"},{"key":"1247_CR56","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/sj.bmt.1701909","volume":"24","author":"S Dix","year":"1999","unstructured":"Dix S, Cord M, Howard S, Coon J, Belt R, Geller R (1999) Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy. Bone Marrow Transplant 24:561\u2013566","journal-title":"Bone Marrow Transplant"},{"key":"1247_CR57","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.21996","volume":"107","author":"HJ Droogendijk","year":"2006","unstructured":"Droogendijk HJ, Kluin-Nelemans HJC, van Doormaal JJ, Oranje AR, van de Loosdrecht AA, van Daele PLA (2006) Imatinibmesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer 107:345\u2013351","journal-title":"Cancer"},{"key":"1247_CR58","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jaci.2008.12.005","volume":"123","author":"A Due\u00f1as-Laita","year":"2009","unstructured":"Due\u00f1as-Laita A, Ruiz-Mu\u00f1oz P, Armentia A, Pinacho F, Mart\u00edn-Armentia B (2009) Successful treatment of chronic drug-resistant urticaria with alprazolam. J Allergy Clin Immunol 123:504\u2013505","journal-title":"J Allergy Clin Immunol"},{"key":"1247_CR59","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.jaci.2003.07.004","volume":"112","author":"SM Duffy","year":"2003","unstructured":"Duffy SM, Lawley WJ, Kaur D, Yang W, Bradding P (2003) Inhibition of human mast cell proliferation and survival by tamoxifen in association with ion channel modulation. J Allergy Clin Immunol 112:965\u2013972","journal-title":"J Allergy Clin Immunol"},{"key":"1247_CR60","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/1752-1947-4-193","volume":"4","author":"AM Edwards","year":"2010","unstructured":"Edwards AM, Hagberg H (2010) Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case report. J Med Case Rep 4:193","journal-title":"J Med Case Rep"},{"key":"1247_CR61","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1756-0500-4-47","volume":"4","author":"AM Edwards","year":"2011","unstructured":"Edwards AM, Stevens MT, Church MK (2011) The effects of topical sodium cromoglicate on itch and flare in human skin induced by intradermal histamine: a randomised double-blind vehicle controlled intra-subject design trial. BMC Res Notes 4:47","journal-title":"BMC Res Notes"},{"key":"1247_CR62","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejphar.2012.01.039","volume":"680","author":"DS El-Agamy","year":"2012","unstructured":"El-Agamy DS (2012) Anti-allergic effects of nilotinib on mast cell-mediated anaphylaxis like reactions. Eur J Pharmacol 680:115\u2013121","journal-title":"Eur J Pharmacol"},{"key":"1247_CR63","doi-asserted-by":"crossref","unstructured":"El-Feki G, X Zhou, LC Lau, J Pedersen, AF Walls (2011) Inhibitors of dipeptidyl peptidase I (DPPI) as mast cell stabilising agents: the contribution of DPPI in mast cell activation. J Allergy Clin Immunol 127, Suppl. \u2013 Abstracts","DOI":"10.1016\/j.jaci.2010.12.524"},{"key":"1247_CR64","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00277-013-1964-1","volume":"93","author":"P Erben","year":"2014","unstructured":"Erben P, Schwaab J, Metzgeroth G, Horny HP, Jawhar M, Sotlar K, Fabarius A, Teichmann M, Schneider S, Ernst T, M\u00fcller MC, Giehl M, Marx A, Hartmann K, Hochhaus A, Hofmann WK, Cross NC, Reiter A (2014) The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol 93:81\u201388","journal-title":"Ann Hematol"},{"key":"1247_CR65","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/187152806775269303","volume":"5","author":"L Escribano","year":"2006","unstructured":"Escribano L, Akin C, Castells M, Schwartz LB (2006) Current options in the treatment of mast cell mediator-related symptoms in mastocytosis. Inflamm Allergy Drug Targets 5:61\u201377","journal-title":"Inflamm Allergy Drug Targets"},{"key":"1247_CR66","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.aller.2013.07.011","volume":"43","author":"N Eskandari","year":"2015","unstructured":"Eskandari N, Bastan R, Peachell PT (2015) Regulation of human skin mast cell histamine release by PDE inhibitors. Allergol Immunopathol (Madr) 43:37\u201341","journal-title":"Allergol Immunopathol (Madr)"},{"key":"1247_CR67","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF02265162","volume":"45","author":"MD Est\u00e9vez","year":"1996","unstructured":"Est\u00e9vez MD, Vieytes MR, Botana LM (1996) Mitoxantrone induces nonimmunological histamine release from rat mast cells. Inflamm Res 45:113\u2013117","journal-title":"Inflamm Res"},{"key":"1247_CR68","doi-asserted-by":"crossref","unstructured":"Evans E, Gardino A, Hodous B, Davis A, Zhu J, Kohl NE, Lengauer C (2015) Blu-285, a potent and selective inhibitor for hematologic malignancies with KIT exon 17 mutations. ASH Annual Meeting: abstract 568","DOI":"10.1182\/blood.V126.23.568.568"},{"key":"1247_CR69","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S1081-1206(10)60545-5","volume":"99","author":"PR Evora","year":"2007","unstructured":"Evora PR, Simon MR (2007) Role of nitric oxide production in anaphylaxis and its relevance for the treatment of anaphylactic hypotension with methylene blue. Ann Allergy Asthma Immunol 99:306\u2013313","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1247_CR70","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1073\/pnas.92.8.3376","volume":"92","author":"L Facci","year":"1995","unstructured":"Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A (1995) Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A 92:3376\u20133380","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1247_CR71","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bph.12138","volume":"170","author":"DF Finn","year":"2013","unstructured":"Finn DF, Walsh JJ (2013) Twenty-first century mast cell stabilisers. Br J Pharmacol 170:23\u201337","journal-title":"Br J Pharmacol"},{"key":"1247_CR72","first-page":"780824","volume":"2015","author":"A Frenkel","year":"2015","unstructured":"Frenkel A, Roy-Shapira A, Evgeni B, Leonid K, Borer A, Klein M (2015) Life threatening idiopathic recurrent angioedema responding to cannabis. Case Rep Immunol 2015:780824","journal-title":"Case Rep Immunol"},{"key":"1247_CR73","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/0091-6749(93)90076-R","volume":"92","author":"BS Friedman","year":"1993","unstructured":"Friedman BS, Santiago ML, Berkebile C, Metcalfe DD (1993) Comparison of azelastine and chlorpheniramine in the treatment of mastocytosis. J Allergy Clin Immunol 92:520\u2013526","journal-title":"J Allergy Clin Immunol"},{"key":"1247_CR74","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0002-9343(85)90454-1","volume":"78","author":"M Frieri","year":"1985","unstructured":"Frieri M, Alling DW, Metcalfe DD (1985) Comparison of the therapeutic efficacy of cromolyn sodium with that of combined chlorpheniramine and cimetidine in systemic mastocytosis. Results of a double-blind clinical trial. Am J Med 78:9\u201314","journal-title":"Am J Med"},{"key":"1247_CR75","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1213\/01.ane.0000166955.97368.80","volume":"101","author":"T Fujimoto","year":"2005","unstructured":"Fujimoto T, Nishiyama T, Hanaoka K (2005) Inhibitory effects of intravenous anesthetics on mast cell function. Anesth Analg 101:1054\u20131059","journal-title":"Anesth Analg"},{"key":"1247_CR76","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2003-07-2477","volume":"103","author":"G Fumo","year":"2004","unstructured":"Fumo G, Akin C, Metcalfe DD, Neckers L (2004) 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood 103:1078\u20131084","journal-title":"Blood"},{"key":"1247_CR77","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1398-9995.1995.tb02490.x","volume":"50","author":"SJ Galli","year":"1995","unstructured":"Galli SJ, Costa JJ (1995) Mast-cell-leukocyte cytokine cascades in allergic inflammation. Allergy 50:851\u2013862","journal-title":"Allergy"},{"key":"1247_CR78","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s000110050421","volume":"48","author":"BF Gibbs","year":"1999","unstructured":"Gibbs BF, Schmutzler W, Vollrath IB, Brosthardt P, Braam U, Wolff HH, Zwadlo-Klarwasser G (1999) Ambroxol inhibits the release of histamine, leukotrienes and cytokines from human leukocytes and mast cells. Inflamm Res 48:86\u201393","journal-title":"Inflamm Res"},{"key":"1247_CR79","first-page":"345","volume":"198","author":"P Giraldo Castellano","year":"1998","unstructured":"Giraldo Castellano P, Garc\u00eda-Erce JA, Alvarez Alegret R, Arroyo Rubio A, Mayayo Artal P, Vicente C\u00e1mara P, Rubio-F\u00e9lix D, Giralt RM (1998) Interferon alpha and systemic mastocytosis. Analysis of therapeutic efficacy in 6 cases. Rev Clin Esp 198:345\u2013350","journal-title":"Rev Clin Esp"},{"key":"1247_CR80","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood-2010-06-289959","volume":"118","author":"KV Gleixner","year":"2011","unstructured":"Gleixner KV, Mayerhofer M, Cerny-Reiterer S, H\u00f6rmann G, Rix U, Bennett KL, Hadzijusufovic E, Meyer RA, Pickl WF, Gotlib J, Horny HP, Reiter A, Mitterbauer-Hohendanner G, Superti-Furga G, Valent P (2011) KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk-activation and disruption by dasatinib and bosutinib. Blood 118:1885\u20131898","journal-title":"Blood"},{"key":"1247_CR81","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3324\/haematol.2012.079202","volume":"98","author":"KV Gleixner","year":"2013","unstructured":"Gleixner KV, Peter B, Blatt K, Suppan V, Reiter A, Radia D, Hadzijusufovic E, Valent P (2013) Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V. Haematologica 98:1450\u20131457","journal-title":"Haematologica"},{"key":"1247_CR82","first-page":"1039A","volume":"110","author":"J Gotlib","year":"2008","unstructured":"Gotlib J, George TI, Corless C, Linder A, Ruddell A, Akin C, DeAngelo DJ, Kepten I, Lanza C, Heinemann H, Yin O, Gallagher N, Graubert T (2008) The KIT tyrosine kinase inhibitor midostaurine (PKC412) exhibits a high response rate in aggressive systemic mastocytosis (ASM): interim results of a phase II trial. Blood 110:1039A","journal-title":"Blood"},{"key":"1247_CR83","doi-asserted-by":"crossref","unstructured":"Gotlib J, Kluin-Neelemans HC, George TI et al. (2014) Midostaurin (PKC412) demonstrates a high rate of durable responses in patients with advanced systemic mastocytosis: results from the fully accrued global phase 2 CPKC412D2201 trial. Blood;124: ASH Annual Meeting Abstracts; Abstract 636","DOI":"10.1182\/blood.V124.21.636.636"},{"key":"1247_CR84","first-page":"120","volume":"3","author":"G Gri","year":"2012","unstructured":"Gri G, Frossi B, D\u2019Inca F, Danelli L, Betto E, Mion F, Sibilano R, Pucillo C (2012) Mast cell: an emerging partner in immune interaction. Front Immunol 3:120","journal-title":"Front Immunol"},{"key":"1247_CR85","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/bmt.2012.198","volume":"48","author":"T Gromke","year":"2013","unstructured":"Gromke T, Elmaagacli AH, Ditschkowski M, Hegerfeldt Y, Koldehoff M, Hlinka M, Ottinger H, Trenschel R, Beelen DW (2013) Delayed graft-versus-mast-cell effect on systemic mastocytosis with associated clonal haematological non-mast cell lineage disease after allogeneic transplantation. Bone Marrow Transplant 48:732\u2013733","journal-title":"Bone Marrow Transplant"},{"key":"1247_CR86","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/bjh.12265","volume":"161","author":"B Gruson","year":"2013","unstructured":"Gruson B, Lortholary O, Canioni D, Chandesris O, Lanternier F, Bruneau J, Grosbois B, Livideanu C, Larroche C, Durieu I, Barete S, Sevestre H, Diouf M, Chaby G, Marolleau JP, Dubreuil P, Hermine O, Damaj G (2013) Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study. Br J Haematol 161:434\u2013442","journal-title":"Br J Haematol"},{"key":"1247_CR87","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1590\/1516-4446-2012-0977","volume":"35","author":"JA Gurgel","year":"2013","unstructured":"Gurgel JA, Lima-J\u00fanior RC, Rabelo CO, Pessoa BB, Brito GA, Ribeiro RA (2013) Amitriptyline, clomipramine, and maprotiline attenuate the inflammatory response by inhibiting neutrophil migration and mast cell degranulation. Rev Bras Psiquiatr 35:387\u2013392","journal-title":"Rev Bras Psiquiatr"},{"issue":"suppl.2","key":"1247_CR88","first-page":"357","volume":"95","author":"E Hadzijusufovic","year":"2010","unstructured":"Hadzijusufovic E, Peter B, Herrmann H, Schuch, Thaiwong T, Yuzbasiyan-Gurkan V, Pickl W, Willmann M, Valent P (2010) Mutations in KIT predict resistance to several TKI (sorafenib, sunitinib, and masitinib) in neoplastic human and canine mast cell lines. Haematologica 95(suppl.2):357 abs. 0857","journal-title":"Haematologica"},{"key":"1247_CR89","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2567.2012.03627.x","volume":"137","author":"B Haenisch","year":"2012","unstructured":"Haenisch B, N\u00f6then MM, Molderings GJ (2012) Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics. Immunology 137:197\u2013205","journal-title":"Immunology"},{"key":"1247_CR90","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00251-014-0768-3","volume":"66","author":"B Haenisch","year":"2014","unstructured":"Haenisch B, Fr\u00f6hlich H, Herms S, Molderings GJ (2014) Evidence for contribution of epigenetic mechanisms in the pathogenesis of systemic mast cell activation disease. Immunogenetics 66:287\u2013297","journal-title":"Immunogenetics"},{"key":"1247_CR91","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00210-013-0880-1","volume":"386","author":"AF Hagel","year":"2013","unstructured":"Hagel AF, Layritz CM, Hagel WH, Hagel HJ, Hagel E, Dauth W, Kressel J, Regnet T, Rosenberg A, Neurath MF, Molderings GJ, Raithel M (2013) Intravenous infusion of ascorbic acid decreases serum histamine concentrations in patients with allergic and non-allergic diseases. Naunyn Schmiedeberg\u2019s Arch Pharmacol 386:789\u2013793","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"1247_CR92","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00394-014-0810-0","volume":"54","author":"Y Hagenlocher","year":"2015","unstructured":"Hagenlocher Y, Kie\u00dfling K, Sch\u00e4ffer M, Bischoff SC, Lorentz A (2015) Cinnamaldehyde is the main mediator of cinnamon extract in mast cell inhibition. Eur J Nutr 54:1297\u20131309","journal-title":"Eur J Nutr"},{"key":"1247_CR93","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jaci.2011.04.037","volume":"128","author":"MJ Hamilton","year":"2011","unstructured":"Hamilton MJ, Hornick JL, Akin C, Castells MC, Greenberger NJ (2011) Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations. J Allergy Clin Immunol 128:147\u2013152","journal-title":"J Allergy Clin Immunol"},{"key":"1247_CR94","doi-asserted-by":"crossref","first-page":"13283","DOI":"10.1073\/pnas.0702654104","volume":"104","author":"O Hantschel","year":"2007","unstructured":"Hantschel O, Rix U, Schmidt U, B\u00fcrckst\u00fcmmer T, Kneidinger M, Sch\u00fctze G, Colinge J, Bennett KL, Ellmeier W, Valent P, Superti-Furga G (2007) The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A 104:13283\u201313288","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1247_CR95","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jaci.2014.03.007","volume":"134","author":"IT Harvima","year":"2014","unstructured":"Harvima IT, Levi-Schaffer F, Draber P, Friedman S, Polakovicova I, Gibbs BF, Blank U, Nilsson G, Maurer M (2014) Molecular targets on mast cells and basophils for novel therapies. J Allergy Clin Immunol 134:530\u2013544","journal-title":"J Allergy Clin Immunol"},{"key":"1247_CR96","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0145-2126(03)00259-5","volume":"28","author":"AW Hauswirth","year":"2004","unstructured":"Hauswirth AW, Simonitsch-Klupp I, Uffmann M, Koller E, Sperr WR, Lechner K, Valent P (2004) Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res 28:249\u2013257","journal-title":"Leuk Res"},{"key":"1247_CR97","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1158\/1078-0432.CCR-07-4575","volume":"14","author":"MC Heinrich","year":"2008","unstructured":"Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA, Soulieres D, Dirnhofer S, Harlow A, Town A, McKinley A, Supple SG, Seymour J, Di Scala L, van Oosterom A, Herrmann R, Nikolova Z, McArthur AG, Imatinib Target Exploration Consortium Study B2225 (2008) Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res 14:2717\u20132725","journal-title":"Clin Cancer Res"},{"key":"1247_CR98","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ajh.20211","volume":"77","author":"B Hennessy","year":"2004","unstructured":"Hennessy B, Giles F, Cortes J, O\u2019brien S, Ferrajoli A, Ossa G, Garcia-Manero G, Faderl S, Kantarjian H, Verstovsek S (2004) Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience. Am J Hematol 77:209\u2013214","journal-title":"Am J Hematol"},{"key":"1247_CR99","doi-asserted-by":"crossref","first-page":"e2266","DOI":"10.1371\/journal.pone.0002266","volume":"3","author":"O Hermine","year":"2008","unstructured":"Hermine O, Lortholary O, Leventhal PS, Catteau A, Soppelsa F, Baude C, Cohen-Akenine A, Palm\u00e9rini F, Hanssens K, Yang Y, Sobol H, Fraytag S, Ghez D, Suarez F, Barete S, Casassus P, Sans B, Arock M, Kinet JP, Dubreuil P, Moussy A (2008) Case-control cohort study of patients\u2019 perceptions of disability in mastocytosis. PLoS One 3:e2266","journal-title":"PLoS One"},{"key":"1247_CR100","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Ottmann OG, Lauber S, Hughes T, Verhoef G, Schwarer AP, Gratwohl A, Rafferty T, Resta D, Gattermann N (2006) A phase II study of nilotinib, a novel inhibitor of c-Kit, PDGFR, and Bcr-Abl, administered to patients with systemic mastocytosis. Blood 108: Abstract 2703 [ASH Annual Meeting Abstracts]","DOI":"10.1182\/blood.V108.11.2703.2703"},{"key":"1247_CR101","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1007\/s00432-015-1988-0","volume":"141","author":"A Hochhaus","year":"2015","unstructured":"Hochhaus A, Baccarani M, Giles FJ, le Coutre PD, M\u00fcller MC, Reiter A, Santanastasio H, Leung M, Novick S, Kantarjian HM (2015) Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study. J Cancer Res Clin Oncol 141:2047\u20132060","journal-title":"J Cancer Res Clin Oncol"},{"key":"1247_CR102","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejphar.2012.12.003","volume":"700","author":"K Hoffmann","year":"2013","unstructured":"Hoffmann K, Xifr\u00f3 RA, Hartweg JL, Spitzlei P, Meis K, Molderings GJ, von K\u00fcgelgen I (2013) Inhibitory effects of benzodiazepines on the adenosine A(2B) receptor mediated secretion of interleukin-8 in human mast cells. Eur J Pharmacol 700:152\u2013158","journal-title":"Eur J Pharmacol"},{"key":"1247_CR103","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/0091-6749(90)90067-E","volume":"85","author":"RF Horan","year":"1990","unstructured":"Horan RF, Sheffer AL, Austen KF (1990) Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol 85:852\u2013855","journal-title":"J Allergy Clin Immunol"},{"key":"1247_CR104","unstructured":"Ibelgaufts H. (2016.) \u201cMast Cells\u201d in COPE: cytokines and cells online pathfinder encyclopaedia, Available at http:\/\/www.cells-talk.com (accessed March 21, 2016)"},{"key":"1247_CR105","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1124\/jpet.107.125237","volume":"324","author":"BM Jensen","year":"2008","unstructured":"Jensen BM, Beaven MA, Iwaki S, Metcalfe DD, Gilfillan A (2008) Concurrent inhibition of KIT- and Fc\u03b5RI-mediated signaling: coordinated suppression of mast cell activation. J Pharmacol Exp Ther 324:128\u2013138","journal-title":"J Pharmacol Exp Ther"},{"key":"1247_CR106","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1158\/1535-7163.MCT-13-0397","volume":"13","author":"B Jin","year":"2014","unstructured":"Jin B, Ding K, Pan J (2014) Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing beta-catenin signaling. Mol Cancer Ther 13:1217\u20131230","journal-title":"Mol Cancer Ther"},{"key":"1247_CR107","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1080\/07315724.1992.12098241","volume":"11","author":"CS Johnston","year":"1992","unstructured":"Johnston CS, Martin LJ, Cai X (1992) Antihistamine effect of supplemental ascorbic acid and neutrophil chemotaxis. J Am Coll Nutr 11:172\u2013176","journal-title":"J Am Coll Nutr"},{"key":"1247_CR108","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.phrs.2011.04.001","volume":"64","author":"R Joks","year":"2011","unstructured":"Joks R, Durkin HG (2011) Non-antibiotic properties of tetracyclines as anti-allergy and asthma drugs. Pharmacol Res 64:602\u2013609","journal-title":"Pharmacol Res"},{"key":"1247_CR109","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/pbc.20711","volume":"48","author":"E Jones","year":"2007","unstructured":"Jones E, Koyama T, Ho RH, Kuttesch J, Shankar S, Whitlock JA, Cartwright J, Frangoul H (2007) Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy. Pediatr Blood Cancer 48:330\u2013332","journal-title":"Pediatr Blood Cancer"},{"key":"1247_CR110","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1620\/tjem.217.185","volume":"217","author":"I Kaneko","year":"2009","unstructured":"Kaneko I, Suzuki K, Matsuo K, Kumagai H, Owada Y, Noguchi N, Hishinuma T, Ono M (2009) Cysteinyl leukotrienes enhance the degranulation of bone marrow-derived mast cells through the autocrine mechanism. Tohoku J Exp Med 217:185\u2013191","journal-title":"Tohoku J Exp Med"},{"key":"1247_CR111","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1038\/cddis.2010.20","volume":"1","author":"M Karlberg","year":"2010","unstructured":"Karlberg M, Ekoff M, Labi V, Strasser A, Huang D, Nilsson G (2010a) Pro-apoptotic Bax is the major and Bak an auxiliary effector in cytokine deprivation-induced mast cell apoptosis. Cell Death Dis 1:e43","journal-title":"Cell Death Dis"},{"key":"1247_CR112","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.4049\/jimmunol.0903656","volume":"185","author":"M Karlberg","year":"2010","unstructured":"Karlberg M, Ekoff M, Huang DC, Mustonen P, Harvima IT, Nilsson G (2010b) The BH3-mimetic ABT-737 induces mast cell apoptosis in vitro and in vivo: potential for therapeutics. J Immunol 185:2555\u20132562","journal-title":"J Immunol"},{"key":"1247_CR113","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1346-8138.1996.tb04026.x","volume":"23","author":"N Katoh","year":"1996","unstructured":"Katoh N, Hirano S, Yasuno H (1996) Solitary mastocytoma treated with tranilast. J Dermatol 23:335\u2013339","journal-title":"J Dermatol"},{"key":"1247_CR114","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.bjp.0706664","volume":"147","author":"LJ Kay","year":"2006","unstructured":"Kay LJ, Yeo WW, Peachell PT (2006) Prostaglandin E-2 activates EP2 receptors to inhibit human lung mast cell degranulation. Br J Pharmacol 147:707\u2013713","journal-title":"Br J Pharmacol"},{"key":"1247_CR115","doi-asserted-by":"crossref","first-page":"50700","DOI":"10.1074\/jbc.M410800200","volume":"279","author":"P Kempna","year":"2004","unstructured":"Kempna P, Reiter E, Arocks M, Azzi A, Zingg JM (2004) Inhibition of HMC-1 mast cell proliferation by vitamin E. J Biol Chem 279:50700\u201350709","journal-title":"J Biol Chem"},{"key":"1247_CR116","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s10238-006-0114-7","volume":"6","author":"D Kempuraj","year":"2006","unstructured":"Kempuraj D, Castellani ML, Petrarca C, Frydas S, Conti P, Theoharides TC, Vecchiet J (2006) Inhibitory effect of quercetin on tryptase and inetrleukin-6 release, and histidine decarboxylase mRNA transcription by human mast cell-1 cell line. Clin Exp Med 6:150\u2013156","journal-title":"Clin Exp Med"},{"key":"1247_CR117","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/0091-6749(89)90097-3","volume":"83","author":"BV Kettelhut","year":"1989","unstructured":"Kettelhut BV, Berkebile C, Bradley D, Metcalfe DD (1989) A double-blind, placebo-controlled, crossover trial of ketotifen versus hydroxyzine in the treatment of pediatric mastocytosis. J Allergy Clin Immunol 83:866\u2013870","journal-title":"J Allergy Clin Immunol"},{"key":"1247_CR118","first-page":"363","volume":"94","author":"L Kibsgaard","year":"2014","unstructured":"Kibsgaard L, Skjold T, Deleuran M, Vestergaard C (2014) Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis. Acta DermVenereol 94:363\u2013364","journal-title":"Acta DermVenereol"},{"key":"1247_CR119","doi-asserted-by":"crossref","first-page":"e0132467","DOI":"10.1371\/journal.pone.0132467","volume":"10","author":"SR Kinney","year":"2015","unstructured":"Kinney SR, Carlson L, Ser-Dolansky J, Thompson C, Shah S, Gambrah A, Xing W, Schneider SS, Mathias CB (2015) Curcumin ingestion inhibits mastocytosis and suppresses intestinal anaphylaxis in a murine model of food allergy. PLoS One 10:e0132467","journal-title":"PLoS One"},{"key":"1247_CR120","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","volume":"102","author":"HC Kluin-Nelemans","year":"2003","unstructured":"Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, Van\u2019t Wout JW, Verhoef G, Gerrits WB, van Dobbenburgh OA, Pasmans SG, Fijnheer R (2003) Cladribine therapy for systemic mastocytosis. Blood 102:4270\u20134276","journal-title":"Blood"},{"key":"1247_CR121","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.leukres.2008.06.013","volume":"33","author":"HC Kluin-Nelemans","year":"2009","unstructured":"Kluin-Nelemans HC, Ferenc V, van Doormaal JJ, van Iperen C, Peters WG, Akin C, Valent P (2009) Lenalidomide therapy in systemic mastocytosis. Leuk Res 33:e19\u2013e22","journal-title":"Leuk Res"},{"key":"1247_CR122","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1182\/blood.V118.21.5145.5145","volume":"118","author":"S Knapper","year":"2011","unstructured":"Knapper S, Cullis J, Drummond MW, Evely R, Everington T, Hoyle C, McLintock L, Poynton C, Radia D (2011) Midostaurin a multi-targeted oral kinase inhibitor in systemic mastocytosis: report of an open-label compassionate use program in the United Kingdom. Blood 118:5145","journal-title":"Blood"},{"key":"1247_CR123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2011.06.008","volume":"133","author":"PJ Koelink","year":"2012","unstructured":"Koelink PJ, Overbeek SA, Braber S, de Kruijf P, Folkerts G, Smit MJ, Kraneveld AD (2012) Targeting chemokine receptors in chronic inflammatory diseases: an extensive review. Pharmacol Ther 133:1\u201318","journal-title":"Pharmacol Ther"},{"key":"1247_CR124","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1182\/blood-2004-07-2639","volume":"105","author":"M Kohno","year":"2005","unstructured":"Kohno M, Yamasaki S, Tybolewicz VLJ, Saito T (2005) Rapid and large amount of autocrine IL-3 production is responsible for mast cell survival by IgE in the absence of antigen. Blood 105:2059\u20132065","journal-title":"Blood"},{"key":"1247_CR125","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.anai.2010.04.011","volume":"104","author":"K Kontou-Fili","year":"2010","unstructured":"Kontou-Fili K, Filis CI, Voulgari C, Panayiotidis PG (2010) Omalizumab monotherapy for bee sting and unprovoked \u201canaphylaxis\u201d in a patient with systemic mastocytosis and undetectable specific IgE. Ann Allergy Asthma Immunol 104:537\u2013539","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1247_CR126","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1398-9995.2006.00997.x","volume":"61","author":"MT Krauth","year":"2006","unstructured":"Krauth MT, Majlesi Y, Sonneck K, Samorapoompichit P, Ghannadan M, Hauswirth AW, Baghestanian M, Schernthaner GH, Worda C, Muller MR, Sperr WR, Valent P (2006) Effects of various statins on cytokine-dependent growth and IgE-dependent release of histamine in human mast cells. Allergy 61:281\u2013288","journal-title":"Allergy"},{"key":"1247_CR127","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.exphem.2006.09.008","volume":"35","author":"MT Krauth","year":"2007","unstructured":"Krauth MT, B\u00f6hm A, Agis H, Sonneck K, Samorapoompichit P, Florian S, Sotlar K, Valent P (2007) Effects of the CD33-targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human mast cells and blood basophils. Exp Hematol 35:108\u2013116","journal-title":"Exp Hematol"},{"key":"1247_CR128","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/MOH.0b013e3283366bf4","volume":"17","author":"U Krug","year":"2010","unstructured":"Krug U, L\u00fcbbert M, B\u00fcchner T (2010) Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest? Curr Opin Hematol 17:85\u201390","journal-title":"Curr Opin Hematol"},{"key":"1247_CR129","doi-asserted-by":"crossref","first-page":"S412","DOI":"10.1016\/S0091-6749(99)70156-9","volume":"103","author":"M Kurosawa","year":"1999","unstructured":"Kurosawa M, Amano H, Kanbe N, Igarashi Y, Nagata H, Yamashita T, Kurimoto F, Miyachi Y (1999) Response to cyclosporin and low-dose methylprednisolone in aggressive systemic mastocytosis. J Allergy Clin Immunol 103:S412\u2013S420","journal-title":"J Allergy Clin Immunol"},{"key":"1247_CR130","unstructured":"Kurzen H. (2009) Neramexane for the treatment of mast cellmediated diseases. Patent application WO2010\/069595"},{"key":"1247_CR131","doi-asserted-by":"crossref","unstructured":"Kvasnicka HM, Thiele J, Bueso-Ramos CE, Kamalanabhaiah S, Cortes JE, Kantajian H, Verstovsek S (2014) Changes in activated bone marrow macrophages and mast cells in patients with myelofibrosis following ruxolitinib therapy. ASH Meeting abstract 3184","DOI":"10.1182\/blood.V124.21.3184.3184"},{"key":"1247_CR132","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.exer.2006.07.008","volume":"83","author":"UW Laengle","year":"2006","unstructured":"Laengle UW, Markstein R, Pralet D, Seewald W, Roman D (2006) Effect of GLC756, a novel mixed dopamine D1 receptor antagonist an dopamine D2 receptor agonist, on TNF-alpha release in vitro from activated rat mast cells. Exp Eye Res 83:1335\u20131339","journal-title":"Exp Eye Res"},{"key":"1247_CR133","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.amjmed.2011.02.038","volume":"124","author":"M Laroche","year":"2011","unstructured":"Laroche M, Livideanu C, Paul C, Cantagrel A (2011) Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis. Am J Med 124:776\u2013778","journal-title":"Am J Med"},{"key":"1247_CR134","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/leu.2010.109","volume":"24","author":"T Lasho","year":"2010","unstructured":"Lasho T, Tefferi A, Pardanani A (2010) Inhibition of JAK-STAT signaling by TG101348: a novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells. Leukemia 24:1378\u20131380","journal-title":"Leukemia"},{"key":"1247_CR135","doi-asserted-by":"crossref","unstructured":"Lasho T, Finke C, Zblewski D et al. (2016) Concurrent activating KIT mutations in systemic mastocytosis. Br J Haematol 173:153\u2013156","DOI":"10.1111\/bjh.13560"},{"key":"1247_CR136","doi-asserted-by":"crossref","unstructured":"Lau HY, Kam\u00a0MF (2005) Inhibition of mast cell histamine release by specific phosphodiesterase inhibitors. Inflamm Res 54(Supplement 1):05\u201306","DOI":"10.1007\/s00011-004-0401-2"},{"key":"1247_CR137","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00394-012-0353-1","volume":"52","author":"S Lechowski","year":"2013","unstructured":"Lechowski S, Feilhauer K, Staib L, Co\u00ebffier M, Bischoff SC, Lorentz A (2013) Combined arginine and glutamine decrease release of de novo synthesized leukotrienes and expression of proinflammatory cytokines in activated human intestinal mast cells. Eur J Nutr 52:505\u2013512","journal-title":"Eur J Nutr"},{"key":"1247_CR138","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.pharep.2014.12.016","volume":"67","author":"YS Lee","year":"2015","unstructured":"Lee YS, Kim MS, Lee DH, Kwon TH, Song HH, Oh SR, do Yoon Y (2015) Luteolin 8-C-\u03b2-fucopyranoside downregulates IL-6 expression by inhibiting MAPKs and the NF-\u03baB signaling pathway in human monocytic cells. Pharmacol Rep 67:581\u2013587","journal-title":"Pharmacol Rep"},{"key":"1247_CR139","doi-asserted-by":"crossref","first-page":"903541","DOI":"10.1155\/2015\/903541","volume":"2015","author":"S Lieberoth","year":"2015","unstructured":"Lieberoth S, Thomsen SF (2015) Cutaneous and gastrointestinal symptoms in two patients with systemic mastocytosis successfully treated with omalizumab. Case Rep Med 2015:903541","journal-title":"Case Rep Med"},{"key":"1247_CR140","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.21561","volume":"84","author":"KH Lim","year":"2009","unstructured":"Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A (2009) Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 84:790\u2013794","journal-title":"Am J Hematol"},{"key":"1247_CR141","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.exphem.2008.05.001","volume":"36","author":"TY Lin","year":"2008","unstructured":"Lin TY, Bear M, Du Z, Foley KP, Ying W, Barsoum J, London C (2008) The novel HSP90 inhibitor STA-9090 exhibits activity against KIT-dependent and -independent malignant mast cell tumors. Exp Hematol 36:1266\u20131277","journal-title":"Exp Hematol"},{"key":"1247_CR142","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1182\/blood-2009-07-231985","volume":"115","author":"TY Lin","year":"2010","unstructured":"Lin TY, Fenger J, Murahari S, Bear MD, Kulp SK, Wang D, Chen CS, Kisseberth WC, London CA (2010) AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated KIT. Blood 115:4217\u20134225","journal-title":"Blood"},{"key":"1247_CR143","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/ced.12488","volume":"40","author":"AD Lock","year":"2015","unstructured":"Lock AD, McNamara CJ, Rustin MH (2015) Sustained improvement in urticaria pigmentosa and pruritus in a case of indolent systemic mastocytosis treated with cladribine. Clin Exp Dermatol 40:142\u2013145","journal-title":"Clin Exp Dermatol"},{"key":"1247_CR144","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00018-010-0587-0","volume":"68","author":"A Lundequist","year":"2011","unstructured":"Lundequist A, Pejler G (2011) Biological implications of preformed mast cell mediators. Cell Mol Life Sci 68:965\u2013975","journal-title":"Cell Mol Life Sci"},{"key":"1247_CR145","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1159\/000316353","volume":"153","author":"Z Ma","year":"2010","unstructured":"Ma Z, Tovar JP, Kwong KY, Paek D (2010) Pimecrolimus induces apoptosis of mast cells in a murine model of cutaneous mastocytosis. Int Arch Allergy Immunol 153:413\u2013418","journal-title":"Int Arch Allergy Immunol"},{"key":"1247_CR146","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1365-2125.1989.tb05339.x","volume":"27","author":"AI Mallet","year":"1989","unstructured":"Mallet AI, Norris P, Rendell NB, Wong E, Greaves MW (1989) The effect of disodium cromoglycate and ketotifen on the excretion of histamine and N tau-methylimidazole acetic acid in urine of patients with mastocytosis. Br J Clin Pharmacol 27:88\u201391","journal-title":"Br J Clin Pharmacol"},{"key":"1247_CR147","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.critrevonc.2013.12.011","volume":"91","author":"I Marech","year":"2014","unstructured":"Marech I, Patruno R, Zizzo N, Gadaleta C, Introna M, Zito AF, Gadaleta CD, Ranieri G (2014) Masitinib (AB1010), from canine tumor model to human clinical development: where we are? Crit Rev Oncol Hematol 91:98\u2013111","journal-title":"Crit Rev Oncol Hematol"},{"key":"1247_CR148","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0022-3565(25)22681-7","volume":"240","author":"DL Marquardt","year":"1987","unstructured":"Marquardt DL, Gruber HE, Walker LL (1987) Ribavirin inhibits mast cell mediator release. J Pharmacol Exp Ther 240:145\u2013149","journal-title":"J Pharmacol Exp Ther"},{"key":"1247_CR149","first-page":"1607","volume":"19","author":"I Marton","year":"2015","unstructured":"Marton I, P\u00f3sfai \u00c9, Borb\u00e9nyi Z, B\u00f6d\u00f6r C, Papp G, Demeter J, Korom I, Varga E, Bata-Cs\u00f6rg\u0151 Z (2015) Therapeutic challenge during the long-term follow-up of a patient with indolent systemic mastocytosis with extensive cutaneous involvement. Eur Rev Med Pharmacol Sci 19:1607\u20131609","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1247_CR150","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1164\/rccm.200503-361OC","volume":"173","author":"S Matsubara","year":"2006","unstructured":"Matsubara S, Li G, Takeda K, Loader JE, Pine P, Masuda ES, Miyahara N, Miyahara S, Lucas JJ, Dakhama A, Gelfand EW (2006) Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness. Am J Respir Crit Care Med 173:56\u201363","journal-title":"Am J Respir Crit Care Med"},{"key":"1247_CR151","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.phrs.2014.05.006","volume":"86","author":"G Mattace Raso","year":"2014","unstructured":"Mattace Raso G, Russo R, Calignano A, Meli R (2014) Palmitoylethanolamide in CNS health and disease. Pharmacol Res 86:32\u201341","journal-title":"Pharmacol Res"},{"key":"1247_CR152","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3109\/09546634.2012.671909","volume":"24","author":"M Maurer","year":"2013","unstructured":"Maurer M, Magerl M, Metz M, Weller K, Siebenhaar F (2013) Miltefosine: a novel treatment option for mast cell-mediated diseases. J Dermatolog Treat 24:244\u2013249","journal-title":"J Dermatolog Treat"},{"key":"1247_CR153","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature14022","volume":"519","author":"BD McNeil","year":"2015","unstructured":"McNeil BD, Pundir P, Meeker S, Han L, Undem BJ, Kulka M, Dong X (2015) Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature 519:237\u2013241","journal-title":"Nature"},{"key":"1247_CR154","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s13148-010-0011-5","volume":"1","author":"SM Meeran","year":"2010","unstructured":"Meeran SM, Ahmed A, Tollefsbol TO (2010) Epigenetic targets of bioactive dietary components for cancer prevention and therapy. Clin Epigenetics 1:101\u2013116","journal-title":"Clin Epigenetics"},{"key":"1247_CR155","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s00011-007-6172-9","volume":"56","author":"YD Min","year":"2007","unstructured":"Min YD, Choi CH, Bark H, Son HY, Park HH, Lee S, Park JW, Park EK, Shin HI, Kim SH (2007) Quercetin inhibits expression of inflammatory cytokines through attenuation of NF-kappaB and p38 MAPK in HMC-1 human mast cell line. Inflamm Res 56:210\u2013215","journal-title":"Inflamm Res"},{"key":"1247_CR156","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.critrevonc.2014.09.001","volume":"93","author":"GJ Molderings","year":"2015","unstructured":"Molderings GJ (2015) The genetic basis of mast cell activation disease\u2014looking through a glass darkly. Crit Rev Oncol Hematol 93:75\u201389","journal-title":"Crit Rev Oncol Hematol"},{"key":"1247_CR157","doi-asserted-by":"crossref","unstructured":"Molderings GJ (2016) Transgenerational transmission of systemic mast cell activation disease-genetic and epigenetic features. Transl Res.","DOI":"10.1016\/j.trsl.2016.01.001"},{"key":"1247_CR158","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/00365520701245744","volume":"42","author":"GJ Molderings","year":"2007","unstructured":"Molderings GJ, Kolck UW, Scheurlen C, Br\u00fcss M, Homann J, Von K\u00fcgelgen I (2007) Multiple novel alterations in KIT tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder. Scand J Gastroenterol 42:1045\u20131053","journal-title":"Scand J Gastroenterol"},{"key":"1247_CR159","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00251-010-0474-8","volume":"62","author":"GJ Molderings","year":"2010","unstructured":"Molderings GJ, Meis K, Kolck UW, Homann J, Frieling T (2010) Comparative analysis of mutation of tyrosine kinase KIT in mast cells from patients with systemic mast cell activation syndrome and healthy subjects. Immunogenetics 62:721\u2013727","journal-title":"Immunogenetics"},{"key":"1247_CR160","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1756-8722-4-10","volume":"4","author":"GJ Molderings","year":"2011","unstructured":"Molderings GJ, Brettner S, Homann J, Afrin LB (2011a) Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol 4:10","journal-title":"J Hematol Oncol"},{"key":"1247_CR161","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2169\/internalmedicine.50.4640","volume":"50","author":"GJ Molderings","year":"2011","unstructured":"Molderings GJ, Raithel M, Kratz F, Azemar M, Haenisch B, Harzer S, Homann J (2011b) Omalizumab treatment of systemic mast cell activation disease: experiences from four cases. Intern Med 50:1\u20135","journal-title":"Intern Med"},{"key":"1247_CR162","doi-asserted-by":"crossref","first-page":"e76241","DOI":"10.1371\/journal.pone.0076241","volume":"8","author":"GJ Molderings","year":"2013","unstructured":"Molderings GJ, Haenisch B, Bogdanow M, Fimmers R, N\u00f6then MM (2013a) Familial occurrence of systemic mast cell activation disease. PLoS One 8:e76241","journal-title":"PLoS One"},{"key":"1247_CR163","first-page":"170","volume":"8","author":"GJ Molderings","year":"2013","unstructured":"Molderings GJ, Haenisch B, Homann J, Wilhelm T, Huber M (2013b) Neue Angriffspunkte der 1-4-Benzodiazepine in der mastzelspezifischen immunsuppressiven Therapie der sytemischen Mastzell\u00fcberaktivit\u00e4tserkrankung. Gastroenterologe 8:170 abstract","journal-title":"Gastroenterologe"},{"key":"1247_CR164","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1055\/s-0034-1370055","volume":"139","author":"GJ Molderings","year":"2014","unstructured":"Molderings GJ, Homann J, Brettner S, Raithel M, Frieling T (2014) Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. Dtsch Med Wochenschr 139:1523\u20131534","journal-title":"Dtsch Med Wochenschr"},{"key":"1247_CR165","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ejphar.2006.10.021","volume":"555","author":"PD Moon","year":"2007","unstructured":"Moon PD, Lee BH, Jeong HJ, An HJ, Park SJ, Kim HR, Ko SG, Um JY, Hong SH, Kim HM (2007) Use of scopoletin to inhibit the production of inflammatory cytokines through inhibition of the IkB\/NF-kB signal cascade in the human mast cell line HMC-1. Eur J Pharmacol 555:218\u2013225","journal-title":"Eur J Pharmacol"},{"key":"1247_CR166","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0162-3109(94)90002-7","volume":"27","author":"M Mousli","year":"1994","unstructured":"Mousli M, Hugli TE, Landry Y, Bronner C (1994) Peptidergic pathway in human skin and rat peritoneal mast cell activation. Immunopharmacology 27:1\u201311","journal-title":"Immunopharmacology"},{"key":"1247_CR167","unstructured":"Moussy A, Kinet JP (2014) Treatment of mastocytosis with masitinib. US Patent Application"},{"key":"1247_CR168","doi-asserted-by":"crossref","first-page":"6941","DOI":"10.1158\/0008-5472.CAN-08-4004","volume":"69","author":"T M\u00fchlenberg","year":"2009","unstructured":"M\u00fchlenberg T, Zhang Y, Wagner AJ, Grabellus F, Bradner J, Taeger G, Lang H, Taguchi T, Schuler M, Fletcher JA, Bauer S (2009) Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res 69:6941\u20136950","journal-title":"Cancer Res"},{"key":"1247_CR169","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.intimp.2011.02.026","volume":"11","author":"MA Nader","year":"2011","unstructured":"Nader MA (2011) Inhibition of anaphylaxis like reaction and mast cell activation by sitagliptin. Int Immunopharmacol 11:1052\u20131056","journal-title":"Int Immunopharmacol"},{"key":"1247_CR170","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.bmt.1705245","volume":"37","author":"R Nakamura","year":"2006","unstructured":"Nakamura R, Chakrabarti S, Akin C, Robyn J, Bahceci E, Greene A, Childs R, Dunbar CE, Metcalfe DD, Barrett AJ (2006) A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant 37:353\u2013358","journal-title":"Bone Marrow Transplant"},{"key":"1247_CR171","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF02142532","volume":"23","author":"H Nolte","year":"1988","unstructured":"Nolte H, Stahl Skov P (1988) Inhibition of basophil histamine release by methotrexate. Agents Actions 23:173\u2013176","journal-title":"Agents Actions"},{"key":"1247_CR172","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/all.12672","volume":"70","author":"UB Nurmatov","year":"2015","unstructured":"Nurmatov UB, Rhatigan E, Simons FE, Sheikh A (2015) H1-antihistamines for primary mast cell activation syndromes: a systematic review. Allergy 70:1052\u20131061","journal-title":"Allergy"},{"key":"1247_CR173","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.mce.2013.05.014","volume":"380","author":"E Oppong","year":"2013","unstructured":"Oppong E, Flink N, Cato AC (2013) Molecular mechanisms of glucocorticoid action in mast cells. Mol Cell Endocrinol 380:119\u2013126","journal-title":"Mol Cell Endocrinol"},{"key":"1247_CR174","doi-asserted-by":"crossref","first-page":"AB202","DOI":"10.1016\/j.jaci.2011.12.180","volume":"129","author":"IM Otani","year":"2012","unstructured":"Otani IM, Bhagat M, Newbury RO, Dohil R, Broide DH, Aceves SS (2012) The effect of anti-IL-5 therapy on esophageal mastocytosis in pediatric eosinophilic esophagitis. J Allergy Clin Immunol 129:AB202","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl. 1","key":"1247_CR175","first-page":"197.7","volume":"194","author":"P Paez","year":"2015","unstructured":"Paez P, Ryan J, Taruselli M, Ndaw V (2015) Fluvastatin elicits apoptosis in primary and transformed mast cells (INC6P.305). J Immunol 194(Suppl. 1):197.7","journal-title":"J Immunol"},{"key":"1247_CR176","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s12185-008-0166-4","volume":"88","author":"L Pagano","year":"2008","unstructured":"Pagano L, Valentini CG, Caira M, Rondoni M, Van Lint MT, Candoni A, Allione B, Cattaneo C, Marbello L, Caramatti C, Pogliani EM, Iannitto E, Giona F, Ferrara F, Invernizzi R, Fanci R, Lunghi M, Fianchi L, Sanpaolo G, Stefani PM, Pulsoni A, Martinelli G, Leone G, Musto P (2008) Advanced mast cell disease: an Italian Hematological Multicenter experience. Int J Hematol 88:483\u2013488","journal-title":"Int J Hematol"},{"key":"1247_CR177","doi-asserted-by":"crossref","first-page":"e00066","DOI":"10.1002\/prp2.66","volume":"2","author":"A Paivandy","year":"2014","unstructured":"Paivandy A, Calounova G, Zarnegar B, Ohrvik H, Melo FR, Pejler G (2014) Mefloquine, an anti-malaria agent, causes reactive oxygen species-dependent cell death in mast cells via a secretory granule-mediated pathway. Pharmacol Res Perspect 2:e00066","journal-title":"Pharmacol Res Perspect"},{"key":"1247_CR178","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1182\/blood-2006-04-013805","volume":"109","author":"J Pan","year":"2007","unstructured":"Pan J, Quintas-Cardama A, Kantarjian HM, Akin C, Manshouri T, Lamb P, Cortes JE, Tefferi A, Giles FJ, Verstovsek S (2007) EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood 109:315\u2013322","journal-title":"Blood"},{"key":"1247_CR179","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2165\/11318860-000000000-00000","volume":"23","author":"GS Papaetis","year":"2009","unstructured":"Papaetis GS, Syrigos KN (2009) Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs 23:377\u2013389","journal-title":"BioDrugs"},{"key":"1247_CR180","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/1538-7445.AM2014-746","volume":"74","author":"C Papayannidis","year":"2014","unstructured":"Papayannidis C, Soverini S, Benedittis CD, Abbenante MC, Sartor C, Iacobucci I, Baldazzi C, Ottaviani E, Ferrari A, Guadagnuolo V, Conficoni A, Paolini S, Parisi S, Frabetti F, Piccari S, Grilli S, Lani E, Martinelli G (2014) PKC412 (midostaurin) is safe and highly effective in systemic mastocytosis patients: follow up of a single-center Italian compassionate use. Cancer Res 74:746","journal-title":"Cancer Res"},{"key":"1247_CR181","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/ajh.23459","volume":"88","author":"A Pardanani","year":"2013","unstructured":"Pardanani A (2013) Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management. Am J Hematol 88:612\u2013624","journal-title":"Am J Hematol"},{"key":"1247_CR182","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(03)14115-3","volume":"362","author":"A Pardanani","year":"2003","unstructured":"Pardanani A, Elliott M, Reeder T, Li CY, Baxter EJ, Cross NC, Tefferi A (2003) Imatinib for systemic mast-cell disease. Lancet 362:535\u2013536","journal-title":"Lancet"},{"key":"1247_CR183","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0145-2126(03)00185-1","volume":"28","author":"A Pardanani","year":"2004","unstructured":"Pardanani A, Hoffbrand AV, Butterfield JH, Tefferi A (2004) Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res 28:127\u2013131","journal-title":"Leuk Res"},{"key":"1247_CR184","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3109\/10428190903486220","volume":"51","author":"SA Parikh","year":"2010","unstructured":"Parikh SA, Kantarjian HM, Richie MA, Cortes JE, Verstovsek S (2010) Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis. Leuk Lymphoma 51:269\u2013274","journal-title":"Leuk Lymphoma"},{"key":"1247_CR185","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.burns.2012.07.031","volume":"39","author":"TH Park","year":"2013","unstructured":"Park TH (2013) The effects of botulinum toxin A on mast cell activity: preliminary results. Burns 39:816\u2013817","journal-title":"Burns"},{"key":"1247_CR186","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.21894","volume":"85","author":"C Paul","year":"2010","unstructured":"Paul C, Sans B, Suarez F, Casassus P, Barete S, Lanternier F, Grandpeix-Guyodo C, Dubreuil P, Palm\u00e9rini F, Mansfield CD, Gineste P, Moussy A, Hermine O, Lortholary O (2010) Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol 85:921\u2013925","journal-title":"Am J Hematol"},{"key":"1247_CR187","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.exphem.2010.05.004","volume":"38","author":"B Peter","year":"2010","unstructured":"Peter B, Hadzijusufovic E, Blatt K, Gleixner KV, Pickl WF, Thaiwong T, Yuzbasiyan-Gurkan V, Willmann M, Valent P (2010) KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406). Exp Hematol 38:782\u2013791","journal-title":"Exp Hematol"},{"issue":"5","key":"1247_CR188","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3324\/haematol.2010.031328","volume":"96","author":"B Peter","year":"2011","unstructured":"Peter B, Gleixner KV, Cerny-Reiterer S, Herrmann H, Winter V, Hadzijusufovic E, Ferenc V, Schuch K, Mirkina I, Horny HP, Pickl WF, Mullauer L, Willmann M, Valent P (2011) Polo-like kinase-1 as novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of siRNA and the Polo-like kinase-1 targeting drug BI 2536. Haematologica 96(5):672\u2013680","journal-title":"Haematologica"},{"key":"1247_CR189","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.clinthera.2013.04.001","volume":"35","author":"M Picard","year":"2013","unstructured":"Picard M, Giavina-Bianchi P, Mezzano V, Castells M (2013) Expanding spectrum of mast cell activation disorders: monoclonal and idiopathic mast cell activation syndromes. Clin Ther 35:548\u2013562","journal-title":"Clin Ther"},{"key":"1247_CR190","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1600-0609.2008.01048.x","volume":"80","author":"D Purtill","year":"2008","unstructured":"Purtill D, Cooney J, Sinniah R, Carnley B, Cull G, Augustson B, Cannell P (2008) Dasatinib therapy for systemic mastocytosis: four cases. Eur J Haematol 80:456\u2013458","journal-title":"Eur J Haematol"},{"key":"1247_CR191","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1002\/cncr.26256","volume":"117","author":"A Quint\u00e1s-Cardama","year":"2011","unstructured":"Quint\u00e1s-Cardama A, Jain N, Verstovsek S (2011) Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis. Cancer 117:5439\u20135449","journal-title":"Cancer"},{"key":"1247_CR192","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.3109\/10428194.2012.763121","volume":"54","author":"A Quint\u00e1s-Cardama","year":"2013","unstructured":"Quint\u00e1s-Cardama A, Sever M, Cortes J, Kantarjian H, Verstovsek S (2013) Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis. Leuk Lymphoma 54:1959\u20131964","journal-title":"Leuk Lymphoma"},{"key":"1247_CR193","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2298\/VSP1105444R","volume":"68","author":"M Radojkovi\u0107","year":"2011","unstructured":"Radojkovi\u0107 M, Risti\u0107 S, Colovi\u0107 N, Terzi\u0107 T, Colovi\u0107 M (2011) Response to cladribine in patient with systemic mastocytosis. Vojnosanit Pregl 68:444\u2013446","journal-title":"Vojnosanit Pregl"},{"key":"1247_CR194","doi-asserted-by":"crossref","first-page":"E74","DOI":"10.1002\/ajh.23942","volume":"90","author":"N Randall","year":"2015","unstructured":"Randall N, Courville EL, Baughn L, Afrin L, Ustun C (2015) Bosutinib, a lyn\/btk inhibiting tyrosine kinase inhibitor, is ineffective in advanced systemic mastocytosis. Am J Hematol 90:E74","journal-title":"Am J Hematol"},{"key":"1247_CR195","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3109\/08923973.2011.651222","volume":"34","author":"M Ritter","year":"2012","unstructured":"Ritter M, El-Nour H, Hedblad MA, Butterfield JH, Beck O, Stephanson N, Holst M, Giscombe R, Azmitia EC, Nordlind K (2012) Serotonin and its 5-HT1 receptor in human mastocytosis. Immunopharmacol Immunotoxicol 34:679\u2013685","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"1247_CR196","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.aller.2012.01.005","volume":"41","author":"L Rodrigo","year":"2013","unstructured":"Rodrigo L, Perez-Martinez I, Lucendo AJ (2013) Urticaria pigmentosa in a female patient wth celiac disease: response to a gluten-free diet. Allergol Immunopathol (Madr) 41:128\u2013130","journal-title":"Allergol Immunopathol (Madr)"},{"key":"1247_CR197","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1590\/S1516-31802007000100012","volume":"125","author":"JM Rodrigues","year":"2007","unstructured":"Rodrigues JM, Pazin Filho A, Rodrigues AJ, Vicente WV, Evora PR (2007) Methylene blue for clinical anaphylaxis treatment: a case report. Sao Paulo Med J 125:60\u201362","journal-title":"Sao Paulo Med J"},{"issue":"Suppl","key":"1247_CR198","first-page":"AB132","volume":"127","author":"T Rodriguez","year":"2011","unstructured":"Rodriguez T, Pfeffer M, Levy BD, Castells M (2011) Lipid mediators in cutaneous and systemic mastocytosis and the impact of 5-LO inhibition. J Allergy Clin Immunol 127(Suppl):AB132","journal-title":"J Allergy Clin Immunol"},{"key":"1247_CR199","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nri1650","volume":"5","author":"H Rosen","year":"2005","unstructured":"Rosen H, Goetzl EJ (2005) Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol 5:560\u2013570","journal-title":"Nat Rev Immunol"},{"key":"1247_CR200","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-2141.2009.07918.x","volume":"148","author":"I Ruano","year":"2010","unstructured":"Ruano I, Gargini R, Izquierdo M (2010) Combination of KIT gene silencing and tocopherol succinate may offer improved therapeutic approaches for human mastocytosis. Br J Haematol 148:59\u201368","journal-title":"Br J Haematol"},{"key":"1247_CR201","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2340\/00015555-1080","volume":"91","author":"L Sagi","year":"2011","unstructured":"Sagi L, Solomon M, Baum S, Lyakhovitsky A, Trau H, Barzilai A (2011) Evidence for methotrexate as a useful treatment for steroid-dependent chronic urticaria. Acta Derm Venereol 91:303\u2013306","journal-title":"Acta Derm Venereol"},{"key":"1247_CR202","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.intimp.2005.04.013","volume":"5","author":"C Sandler","year":"2005","unstructured":"Sandler C, Nurmi K, Lindstedt KA, Sorsa T, Golub LM, Kovanen PT, Eklund KK (2005) Chemically modified tetracyclines induce apoptosis in cultured mast cells. Int Immunohistopharmacol 5:1611\u20131621","journal-title":"Int Immunohistopharmacol"},{"key":"1247_CR203","doi-asserted-by":"crossref","unstructured":"Schittenhelm MM, Akmut F, Illing B, Frey J, Schuster K, Ramachandran A, Kanz L, Kampa-Schittenhelm KM (2014) Gain-of-function KIT mutations sensitize the mutant isoform to the type I tyrosine kinase inhibitor crenolanib: a rationale for the therapeutic use in systemic mastocytosis (SM) and core binding factor leukemias (CBFL). ASH-Meeting abstract 2230","DOI":"10.1182\/blood.V124.21.2230.2230"},{"key":"1247_CR204","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00210-015-1093-6","volume":"388","author":"R Seifert","year":"2015","unstructured":"Seifert R (2015) How do basic secretagogues activate mast cells? Naunyn Schmiedeberg\u2019s Arch Pharmacol 388:279\u2013281","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"1247_CR205","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2230.2009.03650.x","volume":"35","author":"T Shimoda","year":"2010","unstructured":"Shimoda T, Liang Z, Suzuki H, Kawana S (2010) Inhibitory effects of antipsychotic and anxiolytic agents on stress-induced degranulation of mouse dermal mast cells. Clin Exp Dermatol 35:531\u2013536","journal-title":"Clin Exp Dermatol"},{"key":"1247_CR206","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00104-013-2642-5","volume":"85","author":"B Sido","year":"2014","unstructured":"Sido B, Dumoulin FL, Homann J, Hertfelder HJ, Bollmann M, Molderings GJ (2014) Surgical interventions in patients with mast cell activation disease. Aspects relevant for surgery using the example of a cholecystectomy. Chirurg 85:327\u2013333","journal-title":"Chirurg"},{"key":"1247_CR207","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/all.12159","volume":"68","author":"F Siebenhaar","year":"2013","unstructured":"Siebenhaar F, F\u00f6rtsch A, Krause K, Weller K, Metz M, Magerl M, Martus P, Church MK, Maurer M (2013) Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial. Allergy 68:949\u2013952","journal-title":"Allergy"},{"key":"1247_CR208","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/blood-2011-08-372425","volume":"119","author":"VR Simhadri","year":"2012","unstructured":"Simhadri VR, Andersen JF, Calvo E, Choi SC, Coligan JE, Borrego F (2012) Human CD300a binds to phosphatidylethanolamine and phosphatidylserine, and modulates the phagocytosis of dead cells. Blood 119:2799\u20132809","journal-title":"Blood"},{"key":"1247_CR209","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.patbio.2004.04.012","volume":"52","author":"J Simon","year":"2004","unstructured":"Simon J, Lortholary O, Caillat-Vigneron N, Raphael M, Martin A, Briere J, Barete S, Hermine O, Casussus P (2004) Interest of interferon alpha in systemic mastocytosis. The french experience and review of the literature. Pathol Biol 52:294\u2013299","journal-title":"Pathol Biol"},{"key":"1247_CR210","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJM197908303010903","volume":"301","author":"NA Soter","year":"1979","unstructured":"Soter NA, Austen KF, Wasserman SI, Soter NA, Austen KF, Wasserman SI (1979) Oral disodium cromoglycate in the treatment of systemic mastocytosis. N Engl J Med 301:465\u2013469","journal-title":"N Engl J Med"},{"key":"1247_CR211","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.bcp.2012.09.028","volume":"84","author":"J Spirkoski","year":"2012","unstructured":"Spirkoski J, Melo FR, Grujic M, Calounova G, Lundequist A, Wernersson S, Pejler G (2012) Mast cell apoptosis induced by siramesine, a sigma-2 receptor agonist. Biochem Pharmacol 84:1671\u20131680","journal-title":"Biochem Pharmacol"},{"key":"1247_CR212","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/sj.bmt.1704627","volume":"34","author":"A Spyridonidis","year":"2004","unstructured":"Spyridonidis A, Thomas AK, Bertz H, Zeiser R, Schmitt-Graff A, Lindemann A, Waller CF, Finke J (2004) Evidence for a graft-versus-mast-cell effect after allogeneic bone marrow transplantation. Bone Marrow Transplant 34:515\u2013519","journal-title":"Bone Marrow Transplant"},{"key":"1247_CR213","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ajh.23924","volume":"90","author":"P Strati","year":"2015","unstructured":"Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Konopleva M, Rajkhowa T, Durand M, Andreeff M, Levis M, Cortes J (2015) Phase I\/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol 90:276\u2013281","journal-title":"Am J Hematol"},{"key":"1247_CR214","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0014-2999(89)90749-8","volume":"167","author":"T Suzuki-Nishimura","year":"1989","unstructured":"Suzuki-Nishimura T, Sano T, Uchida MK (1989) Effects of benzodiazepines on serotonin release from rat mast cells. Eur J Pharmacol 167:75\u201385","journal-title":"Eur J Pharmacol"},{"key":"1247_CR215","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/j.1398-9995.2008.01677.x","volume":"63","author":"M Tachibana","year":"2008","unstructured":"Tachibana M, Wada K, Katayama K, Kamisaki Y, Maeyama K, Kadowaki T, Blumberg RS, Nakajima A (2008) Activation of peroxisome proliferator-activated receptor gamma suppresses mast cell maturation involved in allergic diseases. Allergy 63:1136\u20131147","journal-title":"Allergy"},{"key":"1247_CR216","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood-2004-08-3247","volume":"105","author":"A Tanaka","year":"2005","unstructured":"Tanaka A, Konno M, Muto S, Kambe N, Morii E, Nakahata T, Itai A, Matsuda H (2005) A novel NF-kappa B inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-Kit receptors. Blood 105:2324\u20132331","journal-title":"Blood"},{"key":"1247_CR217","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/01.shk.0000160522.29482.df","volume":"23","author":"C Tang","year":"2005","unstructured":"Tang C, Lan C, Wang C, Liu R (2005) Amelioration of the development of multiple organ dysfunction syndrome by somatostatin via suppression of intestinal mucosal mast cells. Shock 23:470\u2013475","journal-title":"Shock"},{"key":"1247_CR218","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00011-014-0782-9","volume":"64","author":"A Tanimoto","year":"2015","unstructured":"Tanimoto A, Ogawa Y, Oki C, Kimoto Y, Nozawa K, Amano W, Noji S, Shiozaki M, Matsuo A, Shinozaki Y, Matsushita M (2015) Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm Res 64:41\u201351","journal-title":"Inflamm Res"},{"key":"1247_CR219","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM200101253440415","volume":"344","author":"A Tefferi","year":"2001","unstructured":"Tefferi A, Li CY, Butterfield JH, Hoagland HC (2001) Treatment of systemic mast-cell disease with cladribine. N Engl J Med 344:307\u2013309","journal-title":"N Engl J Med"},{"key":"1247_CR220","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJM200402123500723","volume":"350","author":"J Tolar","year":"2004","unstructured":"Tolar J, Tope WD, Neglia JP (2004) Leukotriene-receptor inhibition for the treatment of systemic mastocytosis. N Engl J Med 350:735\u2013736","journal-title":"N Engl J Med"},{"key":"1247_CR221","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/ajcp\/109.3.279","volume":"109","author":"G Topar","year":"1998","unstructured":"Topar G, Staudacher C, Geisen F, Gabl C, Fend F, Herold M, Greil R, Fritsch P, Sepp N (1998) Urticaria pigmentosa: a clinical, hematopathologic, and serologic study of 30 adults. Am J Clin Pathol 109:279\u2013285","journal-title":"Am J Clin Pathol"},{"key":"1247_CR222","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/ACI.0b013e32835571f6","volume":"12","author":"TD Trojan","year":"2012","unstructured":"Trojan TD, Khan DA (2012) Calcineurin inhibitors in chronic urticaria. Curr Opin Allergy Clin Immunol 12:412\u2013420","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"1247_CR223","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1525-1470.2011.01576.x","volume":"29","author":"PJ Turner","year":"2012","unstructured":"Turner PJ, Kemp AS, Rogers M, Mehr S (2012) Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis. Pediatr Dermatol 29:222\u2013223","journal-title":"Pediatr Dermatol"},{"key":"1247_CR224","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/0304-4165(89)90131-1","volume":"991","author":"K Uchida","year":"1989","unstructured":"Uchida K, Mitsui M, Kawakishi S (1989) Monooxygenation of N-acetylhistamine mediated by L-ascorbate. Biochim Biophys Acta 991:377\u2013379","journal-title":"Biochim Biophys Acta"},{"key":"1247_CR225","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","volume":"32","author":"C Ustun","year":"2014","unstructured":"Ustun C, Reiter A, Scott BL, Nakamura R, Damaj G, Kreil S, Shanley R, Hogan WJ, Perales MA, Shore T, Baurmann H, Stuart R, Gruhn B, Doubek M, Hsu JW, Tholouli E, Gromke T, Godley LA, Pagano L, Gilman A, Wagner EM, Shwayder T, Bornh\u00e4user M, Papadopoulos EB, B\u00f6hm A, Vercellotti G, Van Lint MT, Schmid C, Rabitsch W, Pullarkat V, Legrand F, Yakoub-Agha I, Saber W, Barrett J, Hermine O, Hagglund H, Sperr WR, Popat U, Alyea EP, Devine S, Deeg HJ, Weisdorf D, Akin C, Valent P (2014) Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol 32:3264\u20133274","journal-title":"J Clin Oncol"},{"key":"1247_CR226","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1111\/j.1365-2982.2012.01941.x","volume":"24","author":"K Vaali","year":"2012","unstructured":"Vaali K, Lappalainen J, Lin AH, M\u00e4yr\u00e4np\u00e4\u00e4 MI, Kovanen PT, Berstad A, Eklund KK (2012) Imatinib mesylate alleviates diarrhea in a mouse model of intestinal allergy. Neurogastroenterol Motil 24:e325\u2013e335","journal-title":"Neurogastroenterol Motil"},{"key":"1247_CR227","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","volume":"25","author":"P Valent","year":"2001","unstructured":"Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, Marone G, Nu\u00f1ez R, Akin C, Sotlar K, Sperr WR, Wolff K, Brunning RD, Parwaresch RM, Austen KF, Lennert K, Metcalfe DD, Vardiman JW, Bennett JM (2001) Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 25:603\u2013625","journal-title":"Leuk Res"},{"key":"1247_CR228","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","volume":"37","author":"P Valent","year":"2007","unstructured":"Valent P, Akin C, Escribano L, F\u00f6dinger M, Hartmann K, Brockow K, Castells M, Sperr WR, Kluin-Nelemans HC, Hamdy NA, Lortholary O, Robyn J, van Doormaal J, Sotlar K, Hauswirth AW, Arock M, Hermine O, Hellmann A, Triggiani M, Niedoszytko M, Schwartz LB, Orfao A, Horny HP, Metcalfe DD (2007) Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Investig 37:435\u2013453","journal-title":"Eur J Clin Investig"},{"key":"1247_CR229","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1182\/blood-2010-08-292144","volume":"116","author":"P Valent","year":"2010","unstructured":"Valent P, Sperr WR, Akin C (2010) How I treat patients with advanced systemic mastocytosis. Blood 116:5812\u20135817","journal-title":"Blood"},{"key":"1247_CR230","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","volume":"157","author":"P Valent","year":"2012","unstructured":"Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC, Castells M, Escribano L, Hartmann K, Lieberman P, Nedoszytko B, Orfao A, Schwartz LB, Sotlar K, Sperr WR, Triggiani M, Valenta R, Horny HP, Metcalfe DD (2012) Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 157:215\u2013225","journal-title":"Int Arch Allergy Immunol"},{"key":"1247_CR231","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/BF01988039","volume":"18","author":"JJ Doormaal van","year":"1986","unstructured":"van Doormaal JJ, Idema IG, de Monchy JG, Breukelman H, Keyzer JJ, Doorenbos H (1986) Effects of isoprenaline and terbutaline on urinary excretion of histamine and its two main metabolites in systemic mastocytosis. Agents Actions 18:269\u2013272","journal-title":"Agents Actions"},{"key":"1247_CR232","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.jaci.2012.10.015","volume":"131","author":"JJ Doormaal van","year":"2013","unstructured":"van Doormaal JJ, Arends S, Brunekreeft KL, et al. (2013) Prevalence of indolent systemic mastocytosis in a Dutch region. J Allergy Clin Immunol 131:1429\u20131431","journal-title":"J Allergy Clin Immunol"},{"key":"1247_CR233","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","volume":"33","author":"A Vega-Ruiz","year":"2009","unstructured":"Vega-Ruiz A, Cortes JE, Sever M, Manshouri T, Quint\u00e1s-Cardama A, Luthra R, Kantarjian HM, Verstovsek S (2009) Phase II study of imatinibmesylate as therapy for patients with systemic mastocytosis. Leuk Res 33:1481\u20131484","journal-title":"Leuk Res"},{"key":"1247_CR234","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","volume":"14","author":"S Verstovsek","year":"2008","unstructured":"Verstovsek S, Tefferi A, Cortes J, O\u2019Brien S, Garcia-Manero G, Pardanani A, Akin C, Faderl S, Manshouri T, Thomas D, Kantarjian H (2008) Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 14:3906\u20133915","journal-title":"Clin Cancer Res"},{"key":"1247_CR235","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1034\/j.1399-3003.2000.15.09.x","volume":"15","author":"B Vrugt","year":"2000","unstructured":"Vrugt B, Wilson S, Bron A, Shute J, Holgate ST, Djukanovic R, Aalbers R (2000) Low-dose methotrexate treatment in severe glucocorticoid-dependent asthma: effect on mucosal inflammation and in vitro sensitivity to glucocorticoids of mitogen-induced T-cell proliferation. Eur Respir J 15:478\u2013485","journal-title":"Eur Respir J"},{"key":"1247_CR236","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0190-9622(83)70140-4","volume":"9","author":"EA Welch","year":"1983","unstructured":"Welch EA, Alper JC, Bogaars H, Farrell DS (1983) Treatment of bullous mastocytosis with disodium cromoglycate. J Am Acad Dermatol 9:349\u2013353","journal-title":"J Am Acad Dermatol"},{"key":"1247_CR237","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/jid.2008.248","volume":"129","author":"K Weller","year":"2009","unstructured":"Weller K, Artuc M, Jennings G, Friedrichson T, Guhl S, Dos Santos RV, S\u00fcnder C, Zuberbier T, Maurer M (2009) Miltefosine inhibits human mast cell activation and mediator release both in vitro and in vivo. J Invest Dermatol 129:496\u2013498","journal-title":"J Invest Dermatol"},{"key":"1247_CR238","doi-asserted-by":"crossref","first-page":"e33805","DOI":"10.1371\/journal.pone.0033805","volume":"7","author":"Z Weng","year":"2012","unstructured":"Weng Z, Zhang B, Asadi S, Sismanopoulos N, Butcher A, Fu X, Katsarou-Katsari A, Antoniou C, Theoharides TC (2012) Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in humans. PLoS One 7:e33805","journal-title":"PLoS One"},{"key":"1247_CR239","doi-asserted-by":"crossref","unstructured":"Weng Z, Patel AB, Panagiotidou S, Theoharides TC (2015) The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells. J Allergy Clin Immunol\u00a0135:1044\u20131052","DOI":"10.1016\/j.jaci.2014.10.032"},{"key":"1247_CR240","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3109\/10428199609054789","volume":"22","author":"AS Worobec","year":"1996","unstructured":"Worobec AS, Kirshenbaum AS, Schwartz LB, Metcalfe DD (1996) Treatment of three patients with systemic mastocytosis with interferon alpha-2b. Leuk Lymphoma 22:501\u2013508","journal-title":"Leuk Lymphoma"},{"key":"1247_CR241","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40364-016-0056-5","volume":"4","author":"A Yacoub","year":"2016","unstructured":"Yacoub A, Prochaska L (2016) Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis. Biomark Res 4:2","journal-title":"Biomark Res"},{"key":"1247_CR242","doi-asserted-by":"crossref","first-page":"AB77","DOI":"10.1016\/j.jaci.2015.12.260","volume":"137","author":"S Yamaguchi","year":"2016","unstructured":"Yamaguchi S, Okada Y, Matsunaga Y, Nambu F (2016) Effect of ONO-4053 on Fc\u03b5RI stimulated mast cell activation. J Allergy Clin Immunol 137:AB77","journal-title":"J Allergy Clin Immunol"},{"key":"1247_CR243","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1398-9995.2011.02717.x","volume":"67","author":"K Yamaki","year":"2012","unstructured":"Yamaki K, Yoshino S (2012) Tyrosine kinase inhibitor sunitinib relieves systemic and oral antigen-induced anaphylaxes in mice. Allergy 67:114\u2013122","journal-title":"Allergy"},{"key":"1247_CR244","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000314164","volume":"86","author":"Y Yang","year":"2010","unstructured":"Yang Y, Lu JY, Wu X, Summer S, Whoriskey J, Saris C, Reagan JD (2010) G-protein-coupled receptor 35 is a target of the asthma drugs cromolyn disodium and nedocromil sodium. Pharmacology 86:1\u20135","journal-title":"Pharmacology"},{"key":"1247_CR245","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.2169\/internalmedicine.48.2294","volume":"48","author":"C Yoshida","year":"2009","unstructured":"Yoshida C, Takeuchi M, Tsuchiyama J, Sadahira Y (2009) Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha. Intern Med 48:1973\u20131978","journal-title":"Intern Med"},{"key":"1247_CR246","doi-asserted-by":"crossref","first-page":"272","DOI":"10.2340\/0001555561272273","volume":"61","author":"H Zachariae","year":"1981","unstructured":"Zachariae H, Herlin T, Larsen PO (1981) Oral disodium cromoglycate in mastocytosis. Acta Derm Venereol 61:272\u2013273","journal-title":"Acta Derm Venereol"},{"key":"1247_CR247","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.autrev.2010.11.009","volume":"10","author":"M Zen","year":"2011","unstructured":"Zen M, Canova M, Campana C, Bettio S, Nalotto L, Rampudda M, Ramonda R, Iaccarino L, Doria A (2011) The kaleidoscope of glucorticoid effects on immune system. Autoimmun Rev 10:305\u2013310","journal-title":"Autoimmun Rev"},{"key":"1247_CR248","doi-asserted-by":"crossref","unstructured":"Zhang T, Finn DF, Barlow JW, Walsh JJ (2016) Mast cell stabilisers. Eur J Pharmacol\u00a0778:158\u2013168","DOI":"10.1016\/j.ejphar.2015.05.071"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-016-1247-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00210-016-1247-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-016-1247-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T23:13:34Z","timestamp":1748906014000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00210-016-1247-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,30]]},"references-count":248,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["1247"],"URL":"https:\/\/doi.org\/10.1007\/s00210-016-1247-1","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,30]]}}}